[1]
Koudelakova, V.; Kneblova, M.; Trojanec, R.; Drabek, J.; Hajduch, M. Non-small cell lung cancergenetic predictors. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2013, 157(2), 125-136.
[2]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin., 2017, 67(1), 7-30.
[3]
Navada, S.; Lai, P.; Schwartz, A.G.; Kalemkerian, G.P. Temporal trends in small cell lung cancer: Analysis of the national Surveillance Epidemiology and End-Results (SEER) database. J. Clin. Oncol., 2006, 24(18S), 384S.
[4]
Sher, T.; Dy, G.K.; Adjei, A.A. Small cell lung cancer. Mayo Clin. Proc., 2008, 83(3), 355-367.
[5]
Travis, W.D.; Brambilla, E.; Nicholson, A.G.; Yatabe, Y.; Austin, J.H.M.; Beasley, M.B.; Chirieac, L.R.; Dacic, S.; Duhig, E.; Flieder, D.B.; Geisinger, K.; Hirsch, F.R.; Ishikawa, Y.; Kerr, K.M.; Noguchi, M.; Pelosi, G.; Powell, C.A.; Tsao, M.S.; Wistuba, I. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol., 2015, 10(9), 1243-1260.
[6]
Li, C.M.; Chu, W.Y.; Wong, D.L.; Tsang, H.F.; Tsui, N.B.; Chan, C.M.; Xue, V.W.; Siu, P.M.; Yung, B.Y.; Chan, L.W.; Wong, S.C. Current and future molecular diagnostics in non-small-cell lung cancer. Expert Rev. Mol. Diagn., 2015, 15(8), 1061-10674.
[7]
Tang, Y.; Qiao, G.; Xu, E.; Xuan, Y.; Liao, M.; Yin, G. Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. OncoTargets Ther., 2017, 10, 4527-4534.
[8]
Heist, A.R.S.; Engelman, J.A. SnapShot: Non-small cell lung cancer. Cancer Cell, 2012, 21, 448-448.
[9]
Zhu, Q.G.; Zhang, S.M.; Ding, X.X.; He, B.; Zhang, H.Q. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncol. Target, 2017, 8(34), 57680-57692.
[10]
Pikor, L.A.; Ramnarine, V.R.; Lam, S.; Lam, W.L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer, 2013, 82(2), 179-189.
[11]
Yang, I.A.; Holloway, J.W.; Fong, K.M. Genetic susceptibility to lung cancer and co-morbidities. J. Thorac. Dis., 2013, 5, S454-S462.
[12]
Timmer, J.C.; Salvesen, G.S. Caspase substrates. Cell Death Differ., 2007, 14, 66-72.
[13]
Lüthi, A.U.; Martin, S.J. The CASBAH: A searchable database of caspase substrates. Cell Death Differ., 2007, 14, 641-650.
[14]
Matsuura, K.; Canfield, K.; Feng, W.; Kurokawa, M. Metabolic regulation of apoptosis in cancer. Int. Rev. Cell Mol. Biol., 2016, 327, 43-87.
[15]
Slee, E.A.; Harte, M.T.; Kluck, R.M.; Wolf, B.B.; Casiano, C.A.; Newmeyer, D.D.; Wang, H.G.; Reed, J.C.; Nicholson, D.W.; Alnemri, E.S.; Green, D.R.; Martin, S.J. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol., 1999, 144(2), 281-292.
[16]
Stennicke, H.R.; Jürgensmeier, J.M.; Shin, H.; Deveraux, Q.; Wolf, B.B.; Yang, X.; Zhou, Q.; Ellerby, H.M.; Ellerby, L.M.; Bredesen, D.; Green, D.R.; Reed, J.C.; Froelich, C.J.; Salvesen, G.S. Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol. Chem., 1998, 273, 27084-27090.
[17]
Kurokawa, M.; Kornbluth, S. Caspases and kinases in a death grip. Cell, 2009, 138, 838-854.
[18]
Taylor, R.C.; Cullen, S.P.; Martin, S.J. Apoptosis: Controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol., 2008, 9, 231-241.
[19]
Fernald, K.; Kurokawa, M. Evading apoptosis in cancer. Trends Cell Biol., 2013, 23, 620-633.
[20]
Ambros, V. The functions of animal microRNAs. Nature, 2004, 431, 350-355.
[21]
Bushati, N.; Cohen, S.M. microRNA functions. Annu. Rev. Cell Dev. Biol., 2007, 23, 175-205.
[22]
Krol, J.; Loedige, I.; Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet., 2010, 11, 597-610.
[23]
Palanichamy, J.K.; Rao, D.S. miRNA dysregulation in cancer: Towards a mechanistic understanding. Front. Genet., 2014, 5, 54.
[24]
Gulyaeva, L.F.; Kushlinskiy, N.E. Regulatory mechanisms of microRNA expression. J. Transl. Med., 2016, 14(1), 143.
[25]
Watanabe, K.; Takai, D. Disruption of the expression and function of microRNAs in lung cancer as a result of epigenetic changes. Front. Genet., 2013, 4, 275.
[26]
Hou, J.; Meng, F.; Chan, L.W.; Cho, W.C.; Wong, S.C. Circulating plasma MicroRNAs as diagnostic markers for NSCLC. Front. Genet., 2016, 193 eCollection 2016.
[27]
Wiemer, E.A.C. Prognostic circulating microRNA biomarkers in early-stage non-small cell lung cancer: A Role for miR-150. Clin. Pharmacol. Ther., 2017, 103(6), 968-970.
[28]
Zhao, K.; Cheng, J.; Chen, B.; Liu, Q.; Xu, D.; Zhang, Y. Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer. J. Thorac. Dis., 2017, 9(10), 3735-3746.
[30]
Li, J.C.; Zheng, J.Q. Effect of microRNA-145 on proliferation and apoptosis of human non-small cell lung cancer A549 cells by regulating mTOR signaling pathway. J. Cell. Biochem., 2017. [Epub ahead of print].
[31]
Kang, M.; Shi, J.; Peng, N.; He, S. MicroRNA-211 promotes non-small-cell lung cancer proliferation and invasion by targeting MxA. OncoTargets Ther., 2017, 10, 5667-5675.
[32]
Hou, L.; Luo, P.; Ma, Y.; Jia, C.; Yu, F.; Lv, Z.; Wu, C.; Fu, D. MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer. Oncol. Lett., 2017, 14(4), 4441-4448.
[33]
Wang, L.; Qu, J.; Zhou, L.; Liao, F.; Wang, J. MicroRNA-373 inhibits cell proliferation and invasion via targeting BRF2 in human non-small cell lung cancer A549 cell line. Cancer Res. Treat., 2017, 50(3), 936-949.
[34]
Bhatnagar, P.; Barron-Casella, E.; Bean, C.J.; Milton, J.N.; Baldwin, C.T.; Steinberg, M.H.; Debaun, M.; Casella, J.F.; Arking, D.E. Genome-wide meta-analysis of systolic blood pressure in children with sickle cell disease. PLoS One, 2013, 8(9)e74193
[35]
Gholipour, N.; Ohradanova-Repic, A.; Ahangari, G. A novel report of MiR-4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells. J. Cell. Biochem., 2018, 119(8), 6408-6417.
[36]
Pornour, M.; Ahangari, G.; Hejazi, S.; Deezagi, A. New perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line. Rec. Pat. Anticancer Drug Discov, 2015, 10(2), 214-223.
[37]
Kanehisa, M.; Goto, S.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M. Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res., 2014, 42, D199-D205.
[38]
Triboulet, R.; Chang, H.M.; LaPierre, R.J.; Gregory, R.I. Post-transcriptional control of DGCR8 expression by the microprocessor. RNA, 2009, 15(6), 1005-1011.
[39]
Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer, 2006, 6(11), 857-866.
[40]
Ng, E.K.; Wong, C.L.; Ma, E.S.; Kwong, A. MicroRNAs as new players for diagnosis, prognosis, and therapeutic targets in breast cancer. J. Oncol., 2009, 2009305420
[41]
Li, G.; Fang, J.; Wang, Y.; Wang, H.; Sun, C.C. MiRNA-based therapeutic strategy in lung cancer. Curr. Pharm. Des., 2018, 23(39), 6011-6018.
[42]
Villalobos, P.; Wistuba, I.I. Lung cancer biomarkers. Hematol. Oncol. Clin. North Am., 2017, 31(1), 13-29.
[43]
Saumet, A.; Mathelier, A.; Lecellier, C.H. The potential of microRNAs in personalized medicine against cancers. Biomed Res. Int., 2014, 2014642916
[44]
Sun, C.C.; Li, S.J.; Yuan, Z.P.; Li, D.J. MicroRNA-346 facilitates cell growth and metastasis, and suppresses cell apoptosis in human non-small cell lung cancer by regulation of XPC/ERK/Snail/E-cadherin pathway. Aging (Albany NY), 2016, 8(10), 2509-2524.
[45]
Yang, T.; Thakur, A.; Chen, T.; Yang, L.; Lei, G.; Liang, Y.; Zhang, S.; Ren, H.; Chen, M. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol., 2015, 36(6), 4357-4365.
[46]
Petrovic, N.; Ergun, S. miRNAs as potential treatment targets and treatment options in cancer. Mol. Diagn. Ther., 2018, 22(2), 157-168.
[47]
Meng, W.; Tai, Y.; Zhao, H.; Fu, B.; Zhang, T.; Liu, W.; Chen, G. Downregulation of miR33a-5p in Hepatocellular carcinoma: A possible mechanism for chemotherapy resistance. Med. Sci. Monit., 2017, 23, 1295-1304.
[48]
Shen, M.; Li, M.; Liu, J. Long noncoding RNA HOTTIP promotes nasopharyngeal cancer cell proliferation, migration, and invasion by inhibiting miR-4301. Med. Sci. Monit., 2019, 25, 778-785.
[49]
Sheikhpour, M.; Ahangari, G.; Sadeghizadeh, M.; Khosravi, A.; Derakhshani Deilami, G. Significant changes in D2-like dopamine gene receptors expression associated with non-small-cell lung cancer: Could it be of potential use in the design of future therapeutic strategies? Curr. Cancer Ther. Rev., 2012, 8(4), 304-310.
[50]
Sheikhpour, M.; Ahangari, G.; Sadeghizadeh, M.; Deezagi, A. A novel report of apoptosis in human lung carcinoma cells using selective agonist of D2-like dopamine receptors: A new approach for the treatment of human non-small cell lung cancer. Int. J. Immunopathol. Pharmacol., 2013, 26(2), 393-402.
[51]
Wu, X.Y.; Zhang, C.X.; Deng, L.C.; Xiao, J.; Yuan, X.; Zhang, B.; Hou, Z.B.; Sheng, Z.H.; Sun, L.; Jiang, Q.C. Overexpressed D2 dopamine receptor inhibits non-small cell lung cancer progression through inhibiting NF-κB signaling pathway. Cell. Physiol. Biochem., 2018, 48, 2258-2272.
[52]
Li, J.; Zhu, S.; Kozono, D.; Ng, K.; Futalan, D.; Shen, Y.; Akers, J.C.; Steed, T.; Kushwaha, D.; Schlabach, M.; Carter, B.S.; Kwon, C.H.; Furnari, F.; Cavenee, W.; Elledge, S.; Chen, C.C. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget, 2014, 5(4), 882-893.
[53]
Chetty, R.; Govender, D. Gene of the month: KRAS. J. Clin. Pathol., 2013, 66(7), 548-550.
[54]
McKay, M.M.; Morrison, D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene, 2014, 26(22), 3113-3121.
[55]
Takashima, A.; Faller, D.V. Targeting the RAS oncogene. Expert Opin. Ther. Targets, 2013, 17(5), 507-531.
[56]
Pérez-Ramírez, C.; Cañadas-Garre, M.; Molina, M.Á.; Faus-Dáder, M.J.; Calleja-Hernández, M.Á. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics, 2015, 16(16), 1843-1862.
[57]
Scrima, M.; De Marco, C.; Fabiani, F.; Franco, R.; Pirozzi, G.; Rocco, G.; Ravo, M.; Weisz, A.; Zoppoli, P.; Ceccarelli, M.; Botti, G.; Malanga, D.; Viglietto, G. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): New insights on the role of phosphatydil-inositol-3 kinase. PLoS One, 2012, 7e30427
[58]
Balsara, B.R.; Pei, J.; Mitsuuchi, Y.; Page, R.; Klein-Szanto, A.; Wang, H.; Unger, M.; Testa, J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis, 2004, 25, 2053-2059.
[59]
Cappuzzo, F.; Ligorio, C.; Janne, P.A.; Toschi, L.; Rossi, E.; Trisolini, R.; Paioli, D.; Holmes, A.J.; Magrini, E.; Finocchiaro, G.; Bartolini, S.; Cancellieri, A.; Ciardiello, F.; Patelli, M.; Crino, L.; Varella-Garcia, M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization positive/phospho-Akt positive or never smoker patients with advanced nonsmall-cell lung cancer: The ONCOBELL trial. J. Clin. Oncol., 2007, 25, 2248-2255.
[60]
Tsurutani, J.; Fukuoka, J.; Tsurutani, H.; Shih, J.H.; Hewitt, S.M.; Travis, W.D.; Jen, J.; Dennis, P.A. Evaluation of two phosphorylation sites improves the prognostic significance of akt activation in Non-small-cell lung cancer tumors. J. Clin. Oncol., 2006, 24, 306-314.
[61]
Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc., 2008, 83(5), 584-594.
[62]
Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21(14), 2787-2799.
[63]
Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J.J.; Chewaskulyong, B.; Jiang, H.; Duffield, E.L.; Watkins, C.L.; Armour, A.A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361, 947-957.
[64]
Oxnard, G.R.; Arcila, M.E.; Chmielecki, J.; Ladanyi, M.; Miller, V.A.; Pao, W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res., 2011, 17, 5530-5553.
34
1